Company intelligence / Profile preview

Aruvant Sciences

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Lead therapy ARU-1801 (lentiviral gene therapy) for sickle cell disease is in ongoing Phase 1/2 trials, showing durable, clinically meaningful reduction in disease impact and robust fetal hemoglobin induction with only reduced-intensity conditioning; ARU-2801 (AAV gene therapy for hypophosphatasia) is in preclinical studies demonstrating sustained enzyme activity and disease symptom amelioration in models

Therapeutic areas: HematologyRare Diseases
Modalities: Gene therapyLentiviral gene therapyAdeno-associated virus gene therapy
Industry: Biotech

Drug pipeline

3 assets

ARU-2801

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Partnerships with patient advocacy groups in sickle cell disease and rare disease communities

Beyond the preview

Go deeper on Aruvant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aruvant Sciences.

Explore the full profile